Cas:391248-24-1 Ethyl 5-(4-hydroxyphenyl)oxazole-4-carboxylate manufacturer & supplier

Chemical Name:Ethyl 5-(4-hydroxyphenyl)oxazole-4-carboxylate

CAS.NO:391248-24-1

Synonyms:ethyl 5-(4-hydroxyphenyl)-1,3-oxazole-4-carboxylate

Molecular Formula:C₁₂H₁₁NO₄

Molecular Weight:233.22000

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:410.2ºC at 760mmHg

Density:1.27g/cm3

Index of Refraction:1.561

PSA:72.56000

Exact Mass:233.06900

LogP:2.22390

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like ethyl 5-(4-hydroxyphenyl)-1,3-oxazole-4-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 5-(4-hydroxyphenyl)-1,3-oxazole-4-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 5-(4-hydroxyphenyl)-1,3-oxazole-4-carboxylate Use and application,ethyl 5-(4-hydroxyphenyl)-1,3-oxazole-4-carboxylate technical grade,usp/ep/jp grade.

Related News: As a result, the team identified and prioritized studies that would provide the necessary product and process understanding needed to develop a control strategy, ensure the reproducibility of the product, and meet its intended safety, efficacy, stability, and performance profile regardless of the manufacturing scale. Pyridazine, 6-chloro-4-[4-(2-methoxyphenyl)-1-piperazinyl]-3-phenyl- manufacturers To make Zynteglo, the stem cells taken from the patient’s blood are modified by a virus that carries working copies of the beta-globin gene into the cells. 3α-Fluor-6β-mesylmethyl-17β-acetoxy-5(10)-oestren suppliers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. 3,6-dimethyl-1H-pyrrolo[3,2-c]quinoline vendor & factory CDMOs closely work with companies who want to pursue upcoming innovations in medicines, help cope with shortcomings of internal lab-to-manufacturing scale-up. ,As a result, the team identified and prioritized studies that would provide the necessary product and process understanding needed to develop a control strategy, ensure the reproducibility of the product, and meet its intended safety, efficacy, stability, and performance profile regardless of the manufacturing scale.